{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093951","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.001829+00:00","generated_at":"2026-05-31T10:59:04.458553+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024","bullets":["Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.","CFO Marc Wilson stepping down for personal reasons; search for successor initiated; he will remain until replacement on-boarded.","Paltusotine NDA for acromegaly on track for H2 2024; Phase 3 program for carcinoid syndrome expected to begin by end of 2024.","Topline data from atumelnant Phase 2 studies in CAH and Cushing's syndrome anticipated by end of 2024.","Unrestricted cash $863M as of June 30, 2024; management expects funding into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093951","json":"https://secwatch.observer/filing/0000950170-24-093951.json","markdown":"https://secwatch.observer/filing/0000950170-24-093951.md","text":"https://secwatch.observer/filing/0000950170-24-093951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/0000950170-24-093951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/crnx-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:59:04.458553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90045d0528","claim":"Marc Wilson departed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/0000950170-24-093951-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}